Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Reports Higher Than Expected Loss; India Earnings Roundup

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's largest drug maker Ranbaxy, now controlled by Japan's Daiichi Sankyo, shocked financial analysts with a much higher than expected loss of 679.8 crore rupees ($142 million) during its fourth quarter as compared to a net profit of 187.80 crore ($39 million) in the corresponding quarter of 2007
Advertisement

Related Content

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Piramal Healthcare Says Reports Of Sell-off To GSK Or Sanofi-Aventis “Totally Unfounded”
Piramal Healthcare Says Reports Of Sell-off To GSK Or Sanofi-Aventis “Totally Unfounded”
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
Advertisement
UsernamePublicRestriction

Register

SC069892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel